1. The company provides a mouse model for research suitable to collect reliable data on the causal role, or the absence of it, of excess visceral fat in the development of various physiological disorders. Some data are already available.

2. Based on our research, we hope that ZKPr1, a non-toxic human protein with multiple physiological effects and extraordinary stability in the human circulation, will find its way into the medical practice, particularly for the treatment of obesity (general and visceral) and related disorders.

NOTES:

1. Since ZKPr1 is a human protein, it is very likely that in humans it will be significantly more effective than in mice.

2. Research showing that ZKPr1 is essential for the healthy growth of the human fetus explains why no toxic side effect have been found so far.

3. In case of oral administration, ZKPr1 was available to mice between 9 P.M. and 9 A.M., a very long time compared to the time humans need to take a medication; this means that in humans, a drug will achieve an effective concentration at the site of action during a much shorter time than in the present experiments. In fact, in these experiments the concentration of ZKPr1 in the intestines (the site of its action on fat absorption) most probably had reached a concentration far below the optimum.

4. In the present oral experiments, only 14-18% of ZKPr1 reached the site of action in the gastrointestinal system. With suitable coating this ratio can be certainly at least tripled.